Free Trial
NASDAQ:NYXH

Nyxoah Q1 2025 Earnings Report

Nyxoah logo
$6.03 +0.01 (+0.17%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$6.08 +0.05 (+0.85%)
As of 04/17/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nyxoah EPS Results

Actual EPS
N/A
Consensus EPS
-$0.49
Beat/Miss
N/A
One Year Ago EPS
N/A

Nyxoah Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.64 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nyxoah Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Wednesday, May 14, 2025
Conference Call Time
6:00AM ET

Conference Call Resources

Nyxoah Earnings Headlines

Conditional Issuance of Shares
Something strange going on at Mar-a-Lago
A former government advisor says a $9 trillion AI breakthrough is nearing launch. It may become America’s biggest advantage in the race against China — and a handful of Musk-linked companies could benefit.
Kepler Capital Sticks to Its Buy Rating for Nyxoah (NYXH)
See More Nyxoah Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nyxoah? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nyxoah and other key companies, straight to your email.

About Nyxoah

Nyxoah (NASDAQ:NYXH), a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

View Nyxoah Profile

More Earnings Resources from MarketBeat